Iovance Biotherapeutics, Inc. (IOVA) stock
IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.48−0.05 (-0.66%)
Close on Nov 18, 2026Market cap $3.39BP/E –Yield –
Iovance Biotherapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Iovance Biotherapeutics's pe ratio was 4.0× on Jul 31, 2013.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2013 | Jul 31, 2013 | 4.0× | – |
See a number that looks wrong?